Related references
Note: Only part of the references are listed.Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
Ming-zhe Ma et al.
CANCER LETTERS (2015)
Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion
L. Sleire et al.
ONCOGENE (2015)
Sulfasalazine (SSZ) works cancer stem-like cells (CSCs) via inhibiting xCT signal pathway: Phase 1 study in patients with gastric cancer (EPOC 1205)
Kohei Shitara et al.
CANCER RESEARCH (2014)
Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11
Ross M. Drayton et al.
CLINICAL CANCER RESEARCH (2014)
xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Momoko Yoshikawa et al.
CANCER RESEARCH (2013)
Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia
Takeyuki Wada et al.
CANCER SCIENCE (2013)
CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc- and Thereby Promotes Tumor Growth
Takatsugu Ishimoto et al.
CANCER CELL (2011)
Selective Expression of CD44, a Putative Prostate Cancer Stem Cell Marker, in Neuroendocrine Tumor Cells of Human Prostate Cancer
Ganesh S. Palapattu et al.
PROSTATE (2009)
Sulfasalazine-induced cystine starvation: Potential use for prostate cancer therapy
Daniel W. Doxsee et al.
PROSTATE (2007)
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter:: a new action for an old drug
PW Gout et al.
LEUKEMIA (2001)
Share Paper
